The study will comprise:~A screening period of maximum 28 days;~3 treatment periods during which subjects will be resident at the Clinical Unit from the day before dosing with AZD5718 (Day -1) until at least 48 hours after dosing (Day 3), with discharge on the morning of Day 3 of each treatment period; and~A final visit within 5 to 7 days after the last administration of AZD5718.~Subjects will receive single doses of AZD5718 on 3 occasions, separated by at least 7 days washout, under fasted and fed conditions. Two different formulations (Test Formulation and Reference Formulation) will be given in a randomised order:~Treatment A (Test Formulation): AZD5718 Dose A, fasted~Treatment B (Test Formulation): AZD5718 Dose A, fed~Treatment C (Reference Formulation): AZD5718 Dose A, fasted
This study will be a randomised, open-label, 3-period, 3-treatment, single-dose, crossover study in healthy subjects The study will be performed at a single study centre in the United Kingdom.